Terms: = Endocrine gland cancer AND MSH2, COCA1, 4436, ENSG00000095002, HNPCC, FCC1, HNPCC1, P43246 AND Treatment
60 results:
1. The relationship between DNA mismatch repair gene and other prognostic parameters in pancreatic adenocarcinoma.
Urganci N; Kepil N; Ergun S; Bakkaloglu OK
J Surg Oncol; 2024 Apr; 129(5):876-884. PubMed ID: 38173349
[TBL] [Abstract] [Full Text] [Related]
2. Genomic profile and clinical features of MSI-H and TMB-high pancreatic cancers: real-world data from C-CAT database.
Sakakida T; Ishikawa T; Doi T; Morita R; Kataoka S; Miyake H; Yamaguchi K; Moriguchi M; Sogame Y; Yasuda H; Iwasaku M; Konishi H; Takayama K; Itoh Y
J Gastroenterol; 2024 Feb; 59(2):145-156. PubMed ID: 38006445
[TBL] [Abstract] [Full Text] [Related]
3. Expression of EGFR, PD-L1, and the mismatch repair proteins before and following therapy in malignant serous effusions with metastatic high-grade serous tubo-ovarian carcinoma.
Nikas IP; Park SY; Song MJ; Lee C; Ryu HS
Diagn Cytopathol; 2024 Feb; 52(2):69-75. PubMed ID: 37937321
[TBL] [Abstract] [Full Text] [Related]
4. Deep Learning Can Predict Bevacizumab Therapeutic Effect and Microsatellite Instability Directly from Histology in Epithelial Ovarian cancer.
Wang CW; Lee YC; Lin YJ; Firdi NP; Muzakky H; Liu TC; Lai PJ; Wang CH; Wang YC; Yu MH; Wu CH; Chao TK
Lab Invest; 2023 Nov; 103(11):100247. PubMed ID: 37741509
[TBL] [Abstract] [Full Text] [Related]
5. Therapeutic response to pazopanib: case report and literature review on molecular abnormalities of aggressive prolactinomas.
Medina EJ; Zohdy YM; Porto E; Revuelta Barbero JM; Bray D; Maldonado J; Rodas A; Mayol M; Morales B; Neill S; Read W; Pradilla G; Ioachimescu A; Garzon-Muvdi T
Front Endocrinol (Lausanne); 2023; 14():1195792. PubMed ID: 37529607
[TBL] [Abstract] [Full Text] [Related]
6. DNA Repair Pathway in Ovarian cancer Patients Treated with HIPEC.
Flasarova D; Urban K; Strouhal O; Klos D; Lemstrova R; Dvorak P; Soucek P; Mohelnikova-Duchonova B
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240218
[TBL] [Abstract] [Full Text] [Related]
7. Germline drivers of gynecologic carcinosarcomas.
Sia TY; Gordhandas SB; Birsoy O; Kemel Y; Maio A; Salo-Mullen E; Sheehan M; Hensley ML; Rubinstein M; Makker V; Grisham RN; O'Cearbhaill RE; Roche KL; Mueller JJ; Leitao MM; Sonoda Y; Chi DS; Abu-Rustum NR; Berger MF; Ellenson LH; Latham A; Stadler Z; Offit K; Aghajanian C; Weigelt B; Mandelker D; Liu YL
Gynecol Oncol; 2023 Jul; 174():34-41. PubMed ID: 37149903
[TBL] [Abstract] [Full Text] [Related]
8. The clinical features and management of Lynch syndrome-associated ovarian cancer.
Ran X; Jing H; Li Z
J Obstet Gynaecol Res; 2022 Jul; 48(7):1538-1545. PubMed ID: 35478369
[TBL] [Abstract] [Full Text] [Related]
9. Correlation of mismatch repair deficiency with clinicopathological features and programmed death-ligand 1 expression in thyroid carcinoma.
Qiao PP; Tian KS; Han LT; Ma B; Shen CK; Zhao RY; Zhang Y; Wei WJ; Chen XP
Endocrine; 2022 Jun; 76(3):660-670. PubMed ID: 35366156
[TBL] [Abstract] [Full Text] [Related]
10. Pancreatic cancer with Mutation in BRCA1/2, MLH1, and APC Genes: Phenotype Correlation and Detection of a Novel Germline BRCA2 Mutation.
Vietri MT; D'Elia G; Caliendo G; Albanese L; Signoriello G; Napoli C; Molinari AM
Genes (Basel); 2022 Feb; 13(2):. PubMed ID: 35205366
[TBL] [Abstract] [Full Text] [Related]
11. A Case of Pheochromocytoma as a Subsequent Neoplasm in a Survivor of Childhood Embryonal Rhabdomyosarcoma.
Rodwin RL; Janardan SK; Hofstatter EW; Kadan-Lottick NS
J Pediatr Hematol Oncol; 2022 Mar; 44(2):e585-e588. PubMed ID: 35200227
[TBL] [Abstract] [Full Text] [Related]
12. Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
Rasmussen M; Lim K; Rambech E; Andersen MH; Svane IM; Andersen O; Jensen LH; Nilbert M; Therkildsen C
Gynecol Oncol; 2021 Sep; 162(3):686-693. PubMed ID: 34275654
[TBL] [Abstract] [Full Text] [Related]
13. A Case of a Pathological Complete Response to Neoadjuvant Nivolumab plus Ipilimumab in Periampullary Adenocarcinoma.
Pothuri V; Herndon J; Ballentine SJ; Lim KH; Fields RC
Oncologist; 2021 Sep; 26(9):722-726. PubMed ID: 33982365
[TBL] [Abstract] [Full Text] [Related]
14. Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO group.
Breton C; Meyer A; Malka D; Matias M; De Baere T; Hammel P; Sa Cunha A; Lucchese A; Fuks D; Coriat R; Gallois C; Touchefeu Y; Maillet M; Trouilloud I; Rompteaux P; Carbonnel F; Soularue E
Clin Res Hepatol Gastroenterol; 2021 Nov; 45(6):101607. PubMed ID: 33662776
[TBL] [Abstract] [Full Text] [Related]
15. A correlation study of mismatch repair immunohistochemical protein expression of pancreatic solid tumors in cytology cell blocks and matching surgical specimens.
Teodosescu A; Chan I; Elder J; Wu M
Diagn Cytopathol; 2021 Jun; 49(6):700-705. PubMed ID: 33615705
[TBL] [Abstract] [Full Text] [Related]
16. Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast cancer or Ovarian cancer, 2012-2019.
Kurian AW; Ward KC; Abrahamse P; Bondarenko I; Hamilton AS; Deapen D; Morrow M; Berek JS; Hofer TP; Katz SJ
J Clin Oncol; 2021 May; 39(15):1631-1640. PubMed ID: 33560870
[TBL] [Abstract] [Full Text] [Related]
17. Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression.
Mei Y; Bi WL; Agolia J; Hu C; Giantini Larsen AM; Meredith DM; Al Abdulmohsen S; Bale T; Dunn GP; Abedalthagafi M; Dunn IF
Pituitary; 2021 Jun; 24(3):359-373. PubMed ID: 33492612
[TBL] [Abstract] [Full Text] [Related]
18. Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study.
Majd N; Waguespack SG; Janku F; Fu S; Penas-Prado M; Xu M; Alshawa A; Kamiya-Matsuoka C; Raza SM; McCutcheon IE; Naing A
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33427689
[TBL] [Abstract] [Full Text] [Related]
19. BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer.
Lui GYL; Shaw R; Schaub FX; Stork IN; Gurley KE; Bridgwater C; Diaz RL; Rosati R; Swan HA; Ince TA; Harding TC; Gadi VK; Goff BA; Kemp CJ; Swisher EM; Grandori C
EBioMedicine; 2020 Oct; 60():102988. PubMed ID: 32927276
[TBL] [Abstract] [Full Text] [Related]
20. Diffuse Intratumoral Stromal Inflammation in Ovarian Clear Cell Carcinoma is Associated With Loss of Mismatch Repair Protein and High PD-L1 Expression.
Lin SY; Hang JF; Lin YY; Lai CR; Ho HL; Chou TY
Int J Gynecol Pathol; 2021 Mar; 40(2):148-155. PubMed ID: 32897958
[TBL] [Abstract] [Full Text] [Related]
[Next]
